Top

Canadian Journal of Anesthesia/Journal canadien d'anesthésie

Published in:

01-02-2015 | Review Article/Brief Review

Prevention of venous thromboembolism in the Enhanced Recovery After Surgery (ERAS) setting: an evidence-based review

Authors: Benjamin R. Bell, MD, Pascal E. Bastien, MD, James D. Douketis, MD, on behalf of Thrombosis Canada

Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Issue 2/2015

Abstract

Purpose

To review the evidence surrounding appropriate prophylaxis for venous thromboembolism (VTE) in patients undergoing surgery.

Principal findings

Appropriate prophylactic strategies for surgical patients have been defined in major society guidelines. We review the evidence behind these guidelines in a case-based format, including patients with a high risk of bleeding, history of heparin-induced thrombocytopenia, obesity, and cancer. Selecting the most suitable means for VTE prophylaxis includes evaluating patient, anesthetic, and surgical factors. Nevertheless, pharmacologic VTE prophylaxis will be appropriate for the vast majority of inpatients undergoing surgery.

Conclusions

Venous thromboembolism is a serious but preventable complication of hospitalization, especially among surgical patients. Historically, it has accounted for a high burden of postoperative morbidity and mortality. In the Enhanced Recovery After Surgery era, our aim should be no less ambitious than the eradication of postoperative VTE.

Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107(23 Suppl 1: I22-30.

Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl.): e278S-325S.PubMedCentralPubMed

Stein PD, Matta F, Alrifai A, Rahman A. Trends in case fatality rate in pulmonary embolism according to stability and treatment. Thromb Res 2012; 130: 841-6.PubMedCrossRef

Gould MK, Garcia DA, Wren SM, et al. Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl.): e227S-77S.PubMedCentralPubMed

Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl.): 381S-453S.PubMedCrossRef

Pebanco GD, Kaiser SA, Haines ST. New pharmacologic methods to prevent venous thromboembolism in older adults: a meta-analysis. Ann Pharmacother 2013; 47: 605-16.PubMedCrossRef

Mauermann WJ, Shilling AM, Zuo Z. A comparison of neuraxial block versus general anesthesia for elective total hip replacement: a meta-analysis. Anesth Analg 2006; 103: 1018-25.PubMedCrossRef

Caprini JA, Arcelus JI, Hasty JH, Tamhane AC, Fabrega F. Clinical assessment of venous thromboembolic risk in surgical patients. Semin Thromb Hemost 1991; 17(Suppl 3): 304-12.PubMed

Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85.PubMedCrossRef

10.

Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.PubMedCrossRef

11.

ten Cate H, Hamulyak K. Rivaroxaban for thromboprophylaxis. N Engl J Med 2008; 359: 2174-6.PubMedCrossRef

12.

Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009; 373: 1673-80.PubMedCrossRef

13.

Eriksson BI, Kakkar AK, Turpie AG, et al. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009; 91: 636-44.PubMedCrossRef

14.

Lassen MR, Davidson BL, Gallus A, Pineo G. J Ansell, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost 2007; 5: 2368-75.PubMedCrossRef

15.

Gomez-Outes A, Suarez-Gea ML, Pozo-Hernandez C. Apixaban or enoxaparin for thromboprophylaxis. N Engl J Med 2009; 361: 2100-1.PubMedCrossRef

16.

Jameson SS, Sanders RD, Reed MR. Apixaban vs. enoxaparin after hip replacement. N Engl J Med 2011; 364: 1177.PubMedCrossRef

17.

Anonymous. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000; 355: 1295-302.

18.

Anderson DR, Dunbar MJ, Bohm ER, et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial. Ann Intern Med 2013; 158: 800-6.PubMedCrossRef

19.

Strebel N, Prins M, Agnelli G, Buller HR. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162: 1451-6.PubMedCrossRef

20.

Horlocker TT, Wedel DJ, Rowlingson JC, et al. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition). Reg Anesth Pain Med 2010; 35: 64-101.PubMedCrossRef

21.

Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, Samama CM. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. Eur J Anaesthesiol 2010; 27: 999-1015.PubMedCrossRef

22.

Goldhaber SZ, Savage DD, Garrison RJ, et al. Risk factors for pulmonary embolism. The Framingham Study. Am J Med 1983; 74: 1023-8.PubMedCrossRef

23.

Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity. Exp Rev Cardiovasc Ther 2010; 8: 1711-21.CrossRef

24.

Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355: 809-17.PubMedCrossRef

25.

Cohen AT, Davidson BL, Gallus AS, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 2006; 332: 325-9.PubMedCentralPubMedCrossRef

26.

Eriksson BI, Bauer KA, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Hip-Fracture Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-304.PubMedCrossRef

27.

Turpie AG, Bauer KA, Eriksson BI, Lassen MR; PENTATHALON 2000 Study Steering Committee. Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial. Lancet 2002; 359: 1721-6.PubMedCrossRef

28.

Lassen MR, Bauer KA, Eriksson BI, Turpie AG; European Pentasaccharide Elective Surgery Study (EPHESUS) Steering Committee. Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison. Lancet 2002; 359: 1715-20.PubMedCrossRef

29.

Bauer KA, Eriksson BI, Lassen MR, Turpie AG; Steering Committee of the Pentasaccharide in Major Knee Surgery Study. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001; 345: 1305-10.PubMedCrossRef

30.

Agnelli G, Bergqvist D. Cohen AT, Gallus AS, Gent M; PEGASUS Investigators. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery. Br J Surg 2005; 92: 1212-20.PubMedCrossRef

31.

Warkentin TE, Pai M, Sheppard JI, Schulman S, Spyropoulos AC, Eikelboom JW. Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series. J Thrombosis Haemost 2011; 9: 2389-96.CrossRef

32.

Eikelboom JW, Quinlan DJ, O’Donnell M. Major bleeding, mortality, and efficacy of fondaparinux in venous thromboembolism prevention trials. Circulation 2009; 120: 2006-11.PubMedCrossRef

33.

Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative Management of Antithrombotic Therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(Suppl 2): e326S-50S.PubMedCentralPubMed

34.

Devereaux PJ, Mrkobrada M, Sessler DI, et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370: 1494-503.PubMedCrossRef

35.

Spyropoulos AC, Albaladejo P, Godier A, et al. Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. J Thromb Haemost 2013; 11: 1593-6.PubMedCrossRef

36.

Bell AD, Roussin A, Cartier R, et al. The use of antiplatelet therapy in the outpatient setting: Canadian Cardiovascular Society guidelines. Can J Cardiol 2011; 27 Suppl A: S1-59.

Title: Prevention of venous thromboembolism in the Enhanced Recovery After Surgery (ERAS) setting: an evidence-based review
Authors: Benjamin R. Bell, MD
Pascal E. Bastien, MD
James D. Douketis, MD
on behalf of Thrombosis Canada
Publication date: 01-02-2015
Publisher: Springer US
Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie / Issue 2/2015
Print ISSN: 0832-610X
Electronic ISSN: 1496-8975
DOI: https://doi.org/10.1007/s12630-014-0262-2

At a glance: The STEP trials

Springer Medicine

Prevention of venous thromboembolism in the Enhanced Recovery After Surgery (ERAS) setting: an evidence-based review

Abstract

Purpose

Principal findings

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Principal findings

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2015

Health economics in Enhanced Recovery After Surgery programs

Optimizing pain management to facilitate Enhanced Recovery After Surgery pathways

Enhanced Recovery After Surgery (ERAS)

Perioperative catabolism

Inter-device differences in monitoring for goal-directed fluid therapy

Fluid management and goal-directed therapy as an adjunct to Enhanced Recovery After Surgery (ERAS)